January 20, 2021 -- T-Cure Bioscience has entered into a license agreement with Immunotech Biopharm for the research and development of T-Cure's 800TCR candidate, a human endogenous retrovirus group E (HERV-E)-targeting T-cell receptor (TCR) therapy for renal cell cancer, in China.
T-Cure is currently developing 800TCR in the U.S. in collaboration with the National Heart Lung and Blood Institute (NHLBI) through a formal collaborative research and development agreement. The candidate is being evaluated in a phase I trial at NHLBI for the treatment of metastatic clear cell renal cell carcinoma that failed an angiogenic inhibitor and a checkpoint inhibitor.
HERV-E targets represent a new frontier of TCR targets with significant clinical potential for cancer immunotherapy, according to T-Cure.
Under the agreement, Immunotech will make an upfront payment to T-Cure, which is also eligible to receive additional future development milestone payments and tiered royalties on net sales of the product. Immunotech will have the rights to develop and commercialize 800TCR in China.
Copyright © 2021 scienceboard.net